



Directors, Executives, and Related Persons'

Securities Trading Policy

Ramkhamhaeng Hospital Public Company Limited

Directors, Executives, and Related Persons' Securities Trading Policy

1. Introduction

In order to prevent unfair practices in securities trading arising from the use and/or disclosure of material non-public information that may affect the securities' price, or from the selective disclosure of such information to specific individuals prior to its disclosure to the general public — which may result in an unfair advantage and constitutes an offense under the **Securities and Exchange Act B.E. 2535 (1992)** as amended (the “Securities and Exchange Act”) — the Board of Directors of Ramkhamhaeng Hospital Public Company Limited has therefore established this policy.

2. Objectives

- 2.1 To serve as a guideline for the trading of securities by the Company's directors, executives, and related persons.
- 2.2 To provide guidance on the preparation and disclosure of reports on the holding and changes in holdings of securities and derivatives by directors and executives.
- 2.3 To serve as a guideline for the disclosure and safeguarding of inside information by directors, executives, and related persons.
- 2.4 To ensure that directors, executives, and related persons, as those responsible for the Company's operations, comply with the relevant laws and oversee the proper implementation of this policy within the Company.
- 2.5 To build confidence among shareholders and investors in the Company's securities regarding the prevention of unfair securities trading practices and the transparency of securities holdings by directors and executives.

3. Definitions

For the purpose of this Policy:

- 3.1 “**Director**” means a director of the Company.
- 3.2 “**Board of Directors**” means the Board of Directors of the Company.
- 3.3 “**Executive**” means the Managing Director or the four highest-ranking executives immediately below the Managing Director, including any persons holding positions

equivalent to those of the fourth-ranking executives, and shall also include the Company's Chief Financial Officer or any equivalent position.

3.4 “**Related Persons**” means any employee (including permanent, temporary, or contract employees) or staff member of the Company who holds a position or is in a line of duty that is responsible for, or has access to, inside information.

3.5 “**Inside Information**” means information that has not yet been disclosed to the public and is material to changes in the price or value of the Company's securities, such as:

- 1) Announcement of dividend payment or non-payment;
- 2) Announcement of the Company's profits or losses;
- 3) Any joint venture, merger, acquisition, or disposal of the Company's business;
- 4) Capital increase or capital reduction;
- 5) Tender offer for the securities of another company;
- 6) Changes in significant accounting policies;
- 7) Acquisition or disposal of material assets;
- 8) Changes in the par value of shares.

3.6 “**Impact on Securities Price**” means any effect that causes the price of securities to rise, fall, remain unchanged, or be artificially maintained.

3.7 “**Securities**” shall have the meaning as defined under the Securities and Exchange Act, and in this Policy refers to the securities issued by the Company.

3.8 “**Company**” means Ramkhamhaeng Hospital Public Company Limited, including its subsidiaries and associated companies.

4. Use of Inside Information Policy

Directors, executives, and related persons are prohibited from disclosing inside information to any other person, whether directly or indirectly and by any means, with the knowledge or reasonable belief that such person may use the information for his or her own benefit or for the benefit of others in connection with the purchase or sale of the Company's securities, or in entering into derivative transactions related to such securities.

5. Securities Trading Policy

Directors, executives, and related persons who possess or have access to inside information are prohibited from buying or selling the Company's securities, or entering into any derivative

transactions related to such securities, whether for their own benefit or for the benefit of others, during the period of 30 days prior to the public disclosure of the Company's quarterly and annual financial statements.

They may trade or enter into derivative transactions involving the Company's securities only after such financial statements have been disclosed to the public.

6. Securities Trading Reporting Policy

Directors, executives, and related persons — including their spouses or cohabiting partners, minor children, and any juristic person in which such director, executive, spouse, cohabiting partner, or minor child holds more than 30 percent of the total voting rights, and where such combined shareholding constitutes the largest proportion of voting rights in that juristic person — are required to report their securities holdings and any changes thereto in electronic form through the online system to the Office of the Securities and Exchange Commission (SEC) within the prescribed period from the date of any change in their holdings of the Company's securities or derivatives.

Accordingly, the Board of Directors has established the following guidelines for securities trading and reporting:

- (1) Directors and executives shall notify the Company Secretary at least one day in advance prior to any trading of the Company's shares, in order to facilitate the reporting of changes in securities holdings to the Office of the SEC.
- (2) Directors and executives shall prepare and disclose reports on their holdings and any changes in the holdings of the Company's securities and derivatives to the Office of the SEC, and shall submit a copy of such report to the Company Secretary on the same day the report is submitted to the SEC.